ReviewClinical interventions in aging2013
Eldecalcitol for the treatment of osteoporosis.
Review in Clinical interventions in aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.Archives of osteoporosis · 2022Pooled it
- Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects.Clinical pharmacology in drug development · 2022Trial
- Comparison of Efficacy and Safety of Denosumab with Eldecalcitol or Native Vitamin D in Postmenopausal Chinese Women with Osteoporosis (ESCORT): A Randomized Controlled Trial.Journal of clinical medicine · 2026Article
- Hypercalcemia with the Oral Administration of Active Vitamin D3 and Chinese Herbal Medicine.Internal medicine (Tokyo, Japan) · 2025Article
- Vitamin D therapy in chronic kidney disease: a critical appraisal of clinical trial evidence.Clinical kidney journal · 2024Review
- The Sequential Therapy in Osteoporosis.Indian journal of orthopaedics · 2023Review
- Modulation of the vitamin D/vitamin D receptor system in osteoporosis pathogenesis: insights and therapeutic approaches.Journal of orthopaedic surgery and research · 2023Review
- Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis.Journal of bone and mineral metabolism · 2023Article
- Eldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway in orchiectomized mice.Frontiers in pharmacology · 2022Article
- Cross-Sectional Study on Vitamin D, Zinc Oxide and Fatty Acid Status in a Population with a Moderate to High Risk of AMD Identified by the STARSOphthalmology and therapy · 2021Article
- Rare Sugars: Recent Advances and Their Potential Role in Sustainable Crop Protection.Molecules (Basel, Switzerland) · 2021Review
- Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development.Current medicinal chemistry · 2021Review
- A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model.Journal of exploratory research in pharmacology · 2020Article
- Vitamin D protects against immobilization-induced muscle atrophy via neural crest-derived cells in mice.Scientific reports · 2020Article
- Inhibition of vitamin D analog eldecalcitol on hepatomaOpen medicine (Warsaw, Poland) · 2020Article
- Eldecalcitol effects on osteoblastic differentiation and function in the presence or absence of osteoclastic bone resorption.Experimental and therapeutic medicine · 2019Article
- Severe Hypocalcemia and Resulting Seizure Caused by Vitamin D Deficiency in an Older Patient Receiving Phenytoin: Eldecalcitol and Maxacalcitol Ointment as Potential Therapeutic Options for Hypocalcemia.Case reports in nephrology · 2019Article
- Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.Journal of bone and mineral metabolism · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years by 26% compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol group (71%) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D (25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological action. Increased blood calcium was observed in 21% of patients treated with eldecalcitol, and hypercalcemia (>11.5 mg/dL) occurred in 0.4% of eldecalcitol recipients, so serum calcium concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, especially for elderly patients (who frequently suffer from vitamin D deficiency). This article reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.